title: [A case of massive hepatoma which responded to SMANCS/Lipiodol regimen with intra-arterial infusion].
abstract: Transcatheter arterial chemotherapy (SMANCS/lipiodol) was applied to massive hepatoma, which had a high AFP 213,000 ng/ml, A-P shunt, tumor thrombosis and metastatic lung cancer. After 3 months, the AFP value reduced to 18 ng/ml, massive hepatoma and the A-P shunt disappeared, but AFP-negative nodular hepatoma recurred around initial hepatoma. Each time, we injected SMANCS/lipiodol to the recurring hepatoma. The therapy in the initial stage was not so effective. The portal vein was not observed in the initial stage, but appeared after the second dosage. Metastatic lung cancer was declining in the initial dosage and 23 months later disappeared after the third dosage. The massive hepatoma occupied entirely the rt. lobe of the liver. The patient lived for 4 years, had total admission periods of 190 days and could return to life in society. In this case, we considered that transcatheter arterial chemotherapy (SMANCS/lipiodol) had remarkable effects.
authors.affiliation: Dept. of Gastroenterology, Matsuyama Red Cross Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Kubo
authors.forename: T
authors.initials: T
authors.lastname: Fuchigami
authors.forename: S
authors.initials: S
authors.lastname: Murata
authors.forename: T
authors.initials: T
authors.lastname: Konno
authors.forename: H
authors.initials: H
authors.lastname: Maeda
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000556:secondary; D005500:Follow-Up Studies; D005663:Furans / Q000008:administration & dosage*; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000379:methods; D007459:Iodized Oil / Q000008:administration & dosage* / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008299:Maleic Anhydrides / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D011137:Polystyrenes / Q000008:administration & dosage* / Q000627:therapeutic use; D011379:Prognosis; D012074:Remission Induction; D009353:Zinostatin / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D005663:Furans; D008299:Maleic Anhydrides; D011137:Polystyrenes; C035755:poly(maleic acid-styrene)neocarzinostatin; D007459:Iodized Oil; D009353:Zinostatin